免疫检查点抑制剂的药代动力学特征及其临床影响因素综述
A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors.
作者信息
Liu Jun-Chen, Yu Hong-Jing
机构信息
Department of Clinical Pharmacy, The First People's Hospital of Jiande, Jiande, People's Republic of China.
出版信息
Pharmgenomics Pers Med. 2023 Jan 20;16:29-36. doi: 10.2147/PGPM.S391756. eCollection 2023.
Abstract
Immune checkpoint inhibitors (ICIs) have been shown to be significant in improving the overall survival rate in certain malignancies with poor prognoses. However, only 20-40% of patients achieve long-term benefits, highlighting the relevance of the factors that influence the treatment, which can help clinicians improve their results and guide the development of new immune checkpoint therapies. In this study, the current pharmacokinetic aspects associated with the ICIs and the factors influencing clinical efficacy were characterised, including in terms of drug metabolism, drug clearance, hormonal effects and immunosuppressive effects.
摘要
免疫检查点抑制剂（ICIs）已被证明在提高某些预后不良的恶性肿瘤的总生存率方面具有重要意义。然而，只有20%-40%的患者能获得长期益处，这凸显了影响治疗效果的因素的相关性，这些因素有助于临床医生提高治疗效果并指导新型免疫检查点疗法的研发。在本研究中，对与ICIs相关的当前药代动力学方面以及影响临床疗效的因素进行了表征，包括药物代谢、药物清除、激素效应和免疫抑制效应等方面。
相似文献
1
A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors.免疫检查点抑制剂的药代动力学特征及其临床影响因素综述
Pharmgenomics Pers Med. 2023 Jan 20;16:29-36. doi: 10.2147/PGPM.S391756. eCollection 2023.
2
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.免疫检查点抑制剂的临床药代动力学和药效学。
Clin Pharmacokinet. 2019 Jul;58(7):835-857. doi: 10.1007/s40262-019-00748-2.
3
Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.癌症患者接受免疫检查点抑制剂治疗后发生免疫介导性肝毒性的危险因素：系统评价和荟萃分析。
Expert Opin Drug Saf. 2022 Oct;21(10):1275-1287. doi: 10.1080/14740338.2022.2134854. Epub 2022 Oct 16.
4
Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.中国正在进行的免疫检查点抑制剂 I 期研究。
Oncologist. 2019 Feb;24(Suppl 1):S11-S20. doi: 10.1634/theoncologist.2019-IO-S1-s03.
5
Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.腔道胃肠道恶性肿瘤中的免疫检查点抑制剂：超越微卫星高度不稳定/错配修复缺陷、肿瘤突变负荷和程序性死亡配体1
Immunotherapy. 2022 Aug;14(11):885-902. doi: 10.2217/imt-2022-0012. Epub 2022 Jun 13.
6
The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.抗生素对恶性肿瘤免疫检查点抑制剂疗效的影响：基于 44 个队列的研究。
Int Immunopharmacol. 2021 Mar;92:107303. doi: 10.1016/j.intimp.2020.107303. Epub 2021 Jan 16.
7
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.免疫检查点抑制剂的未来：聚焦肿瘤免疫微环境。
Ann Transl Med. 2020 Sep;8(17):1095. doi: 10.21037/atm-20-3735.
8
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.晚期泌尿生殖系统恶性肿瘤患者接受免疫检查点抑制剂治疗的结局特征。
Urol Oncol. 2021 Jul;39(7):437.e1-437.e9. doi: 10.1016/j.urolonc.2021.01.006. Epub 2021 Jan 23.
9
Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.CD73 表达对 NSCLC 免疫检查点抑制剂疗效的预测价值。
Thorac Cancer. 2020 Apr;11(4):950-955. doi: 10.1111/1759-7714.13346. Epub 2020 Feb 15.
10
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).在完成 2 年免疫检查点抑制剂治疗或在疾病无进展停药后获得持久缓解的晚期和/或转移性非小细胞肺癌患者中的长期结局：多中心真实世界数据（KCSG LU20-11）。
Cancer. 2022 Feb 15;128(4):778-787. doi: 10.1002/cncr.33984. Epub 2021 Oct 27.
引用本文的文献
1
Enhanced potency of immune checkpoint inhibitors against poorly immunological solid tumors by immune stimulatory oncolytic adenoviruses-mediated remodeling of the tumor microenvironment.免疫刺激溶瘤腺病毒介导的肿瘤微环境重塑增强免疫检查点抑制剂对免疫原性差的实体瘤的效力
Mol Med. 2025 May 7;31(1):175. doi: 10.1186/s10020-025-01223-4.
2
Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art.创新全身治疗联合放疗用于骨转移的疗效：欧洲骨转移研究组（GEMO）的最新进展
Cancer Metastasis Rev. 2025 Jan 29;44(1):28. doi: 10.1007/s10555-024-10236-0.
3
Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.免疫检查点抑制剂在移植前肝细胞癌治疗中的应用：肝脏之外的探索。
Int J Mol Sci. 2024 Oct 30;25(21):11676. doi: 10.3390/ijms252111676.
本文引用的文献
1
Strategies to mitigate the toxicity of cancer therapeutics.减轻癌症治疗毒性的策略。
Adv Cancer Res. 2022;155:215-244. doi: 10.1016/bs.acr.2022.02.006. Epub 2022 Mar 21.
2
Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.基于问卷的 PD-1/PD-L1 免疫检查点抑制剂治疗癌症患者免疫相关不良事件的检测。
BMC Cancer. 2021 Mar 24;21(1):314. doi: 10.1186/s12885-021-08006-0.
3
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.基于免疫检查点抑制剂的癌症免疫治疗耐药性：靶点、生物标志物和治疗方法。
Drug Resist Updat. 2020 Dec;53:100718. doi: 10.1016/j.drup.2020.100718. Epub 2020 Jul 15.
4
Liver Cancer Immunity.肝癌免疫
Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):86-103. doi: 10.1002/hep.31416. Epub 2020 Nov 7.
5
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.肿瘤治疗性单克隆抗体的药代动力学/药效学关系：第 2 部分，免疫检查点抑制剂抗体。
Eur J Cancer. 2020 Mar;128:119-128. doi: 10.1016/j.ejca.2020.01.003. Epub 2020 Feb 6.
6
The repertoire of mutational signatures in human cancer.人类癌症中的突变特征谱。
Nature. 2020 Feb;578(7793):94-101. doi: 10.1038/s41586-020-1943-3. Epub 2020 Feb 5.
7
Outcompeting cancer.战胜癌症。
Nat Rev Cancer. 2020 Mar;20(3):187-198. doi: 10.1038/s41568-019-0231-8. Epub 2020 Jan 13.
8
What Is Cancer?什么是癌症？
Perspect Biol Med. 2019;62(4):778-784. doi: 10.1353/pbm.2019.0046.
9
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.肿瘤微环境中的髓系免疫抑制和免疫检查点。
Cell Mol Immunol. 2020 Jan;17(1):1-12. doi: 10.1038/s41423-019-0306-1. Epub 2019 Oct 14.
10
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.展望未来：针对癌症治疗的下一代免疫检查点靶点。
Chemotherapy. 2019;64(2):62-80. doi: 10.1159/000500902. Epub 2019 Aug 6.
Zotero 插件